BSE · 524606
Beryl Drugs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹1 Cr — a 2.57% net margin, versus 2.83% the period before.
Shareholding
As of 2026-06-30
- Promoter27.82%
- Public72.18%
7,309 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.88× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #90 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Beryl Drugs Ltd.(this company) | ₹11 Cr | 25.25 | 1.09 | 4.3% | 2.23% |
AI analysis
AI-generated · google/gemini-2.5-flashBeryl Drugs Ltd. is listed with a market capitalization of Rs 11 Cr. The company reported a profit margin of 223.17% and an EPS of 0.84. Its debt-to-equity ratio stands at 0.5.
Positives
- +The Return on Equity (ROE) is high at 429.63%.
- +The debt-to-equity ratio is 0.5, indicating a moderate level of debt.
Negatives
- −Revenue decreased by 16.99% from Rs 27.1247 Cr in Mar 2024 to Rs 22.5548 Cr in Mar 2025.
- −Net profit decreased by 24.70% from Rs 0.7686 Cr in Mar 2024 to Rs 0.5788 Cr in Mar 2025.
- −The promoter holding has decreased from 27.8161% in Mar 2025 to 27.8161% in Jun 2026.
- −No quarterly EPS figures are disclosed in the provided data.
- −The company's P/E ratio is 26.18, and its EPS is 0.84, which might suggest a valuation concern relative to earnings.
Financial performance
The company's revenue decreased by 16.99% from Rs 27.1247 Cr in Mar 2024 to Rs 22.5548 Cr in Mar 2025. Net profit also declined from Rs 0.7686 Cr in Mar 2024 to Rs 0.5788 Cr in Mar 2025, a decrease of 24.70%. Quarterly revenue has fluctuated, with the latest quarter (Mar 2026) showing revenue of Rs 5.47 Cr and net profit of Rs 0.56 Cr.
Profitability & Returns
Beryl Drugs Ltd. reported a Return on Equity (ROE) of 429.63% and a Return on Capital Employed (ROCE) of 7.5626%. The profit margin is 223.17%. Earnings per share (EPS) for the latest available annual period (Mar 2025) was 1.14.
Balance Sheet
The company has a debt-to-equity ratio of 0.5, indicating some reliance on debt financing. The book value per share is Rs 19.44. No specific details about asset composition or liabilities other than debt are available in the provided data.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Beryl Drugs Ltd. is 27.8161%, while public shareholding stands at 72.1839%. There is no promoter pledge reported (0%). The number of shareholders is 7,309.
Regulatory & Surveillance
The company is not currently under any surveillance measure based on the provided data. There is no information regarding past regulatory actions or specific compliance details.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.